Hematology

Hematology includes companies focused on blood disorders, bone marrow disease, hemoglobinopathies, clotting disorders, and hematologic cancers. Businesses grouped here often sit at the intersection of rare disease, oncology, and precision medicine.

Why watch Hematology

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Hematology news

The latest feed items from companies currently grouped under Hematology.

1. 01
   2026-07-13 10:59 EST

   BMYU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

   Source: BMYBristol-Myers Squibb Company

2. 02
   2026-06-30 23:32 EST

   APTOAptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

   Source: Aptose Biosciences, Inc.

3. 03
   2026-06-30 12:05 EST

   APVOAptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

   Source: Aptevo Therapeutics

4. 04
   2026-06-25 13:46 EST

   BMYBristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

   Source: BMYBristol-Myers Squibb Company

5. 05
   2026-06-25 13:46 EST

   IRONDisc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

   Source: Disc Medicine

6. 06
   2026-06-25 13:46 EST

   APTOAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

   Source: Aptose Biosciences, Inc.

7. 07
   2026-06-25 13:46 EST

   SNDXSyndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

   Source: Syndax Pharmaceuticals

8. 08
   2026-06-25 13:46 EST

   SNDXSyndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

   Source: Syndax Pharmaceuticals

9. 09
   2026-06-25 13:46 EST

   IRONDisc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

   Source: Disc Medicine

10. 10
    2026-06-25 13:46 EST

    BMYMariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

    Source: BMYBristol-Myers Squibb Company

11. 11
    2026-06-25 13:46 EST

    SNDXSyndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

    Source: Syndax Pharmaceuticals

12. 12
    2026-06-25 13:46 EST

    IRONDisc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

    Source: Disc Medicine

13. 13
    2026-06-25 13:46 EST

    IRONDisc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

    Source: Disc Medicine

14. 14
    2026-06-25 13:46 EST

    SNDXSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

    Source: Syndax Pharmaceuticals

15. 15
    2026-06-25 13:46 EST

    BMYIzalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

    Source: BMYBristol-Myers Squibb Company

16. 16
    2026-06-25 13:46 EST

    SNDXSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

    Source: Syndax Pharmaceuticals

17. 17
    2026-06-25 13:46 EST

    BMYBristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

    Source: BMYBristol-Myers Squibb Company

18. 18
    2026-06-25 13:46 EST

    BMYU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

    Source: BMYBristol-Myers Squibb Company

19. 19
    2026-06-25 13:46 EST

    BMYGlobal Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

    Source: BMYBristol-Myers Squibb Company

20. 20
    2026-06-25 13:46 EST

    BMYBristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

    Source: BMYBristol-Myers Squibb Company

Companies in Hematology

8 companies tagged with Hematology.

Frequently Asked Questions